anatibant
Small moleculeexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Bradykinin B2 receptorANTAGONIST
BDKRB2 antagonist
Possible safety concerns?
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(C)c2cccc(OCc3c(Cl)ccc(S(=O)(=O)N4CCC[C@H]4C(=O)NCCCNC(=O)c4ccc(C(=N)N)cc4)c3Cl)c2n1- Mol. weight
- 711.67 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107725 ↗
Also known as
- 1-((2,4-dichloro-3-(((2,4-dimethylquinolin-8-yl)oxy) methyl)phenyl)sulfonyl)-n-(3-((4-(aminoimethyl) phenyl) carbonylamino)propyl)-2(s)-pyrrolidinecarboxamide
- anatibant
- anatibant
- anatibant
- anatibant
- lf 16-0687
- lf16-0687
- lf16-0687
- lf16-0687
- lf16-0687ms
- xy-2405
- xy-2405